The burgeoning landscape of medication for weight management and type 2 diabetes is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant differences in their pharmacological profiles a

Showing promise in the arena of obesity treatment, retatrutide is a different approach. Different from many existing medications, retatrutide operates as a double agonist, simultaneously engaging both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic hormone (GIP) sensors. The